Patents by Inventor David M. Knight

David M. Knight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-TNF Antibodies, Compositions, Methods and Uses
    Publication number: 20090081241
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
    Type: Application
    Filed: November 14, 2008
    Publication date: March 26, 2009
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Anti-TNF Antibodies, Compositions, Methods and Uses
    Publication number: 20090074794
    Abstract: The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof.
    Type: Application
    Filed: November 13, 2008
    Publication date: March 19, 2009
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallen, David Shealy
  • Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
    Publication number: 20090041762
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: December 13, 2005
    Publication date: February 12, 2009
    Inventors: Junming Le, Jan T. Vilcek, Peter E. Daddona, John Ghrayeb, David M. Knight, Scott A. Siegel, David J. Shealy
  • Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
    Patent number: 7393662
    Abstract: The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: July 1, 2008
    Assignee: Centocor, Inc.
    Inventors: George A. Heavner, David M. Knight, John Ghrayeb, Bernard J. Scallon, Thomas C. Nesspor, Chichi Huang
  • Method for treating psoriasis by administering an anti-il-12 antibody
    Patent number: 7279157
    Abstract: The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: October 9, 2007
    Assignee: Centocor, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Anti-TNF antibodies, compositions, methods and uses
    Patent number: 7250165
    Abstract: The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: July 31, 2007
    Assignee: Centocor, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
    Patent number: 7241733
    Abstract: The present invention relates to at least one novel human EPO mimetic CH1 deleted mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic CH1 deleted mimetibody or specified portion or variant, CH1 deleted mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: July 10, 2007
    Assignee: Centocor, Inc.
    Inventors: George A. Heavner, David M. Knight, John Ghrayeb, Bernard J. Scallon, Thomas C. Nesspor, Karen A. Kutoloski
  • Anti-TNF antibody fragments
    Patent number: 7227003
    Abstract: Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: June 5, 2007
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight, Scott A. Siegel
  • Anti-IL-12 antibodies and compositions
    Patent number: 7166285
    Abstract: The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: January 23, 2007
    Assignee: Centocor, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Anti-idiotypic anti-TNF antibodies and related immunoassay methods
    Patent number: 7101674
    Abstract: Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: September 5, 2006
    Assignees: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight, Scott A. Siegel
  • Nucleic acids encoding IL-12 antibody
    Patent number: 7063964
    Abstract: The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: June 20, 2006
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Chimeric immunoglobulin for CD4 receptors
    Patent number: 7037496
    Abstract: Chimeric antibodies for CD4 receptor comprising a variable or antigen binding region of a non-human origin specific for CD4 receptor and a constant region of human origin are disclosed. These antibodies are useful as therapeutic agents for auto-immune disorders.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: May 2, 2006
    Assignee: Centocor, Inc.
    Inventors: John Ghrayeb, David M. Knight, James E. Looney
  • Anti-IL-12 antibodies and compositions thereof
    Patent number: 6902734
    Abstract: The present invention relates to at least one anti-IL-12 antibody, including isolated nucleic acids that encode at least one anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: June 7, 2005
    Assignee: Centocor, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Anti-TNF antibodies and peptides of human tumor necrosis factor
    Publication number: 20040120952
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: August 8, 2003
    Publication date: June 24, 2004
    Applicant: Centocor, Inc
    Inventors: David M. Knight, David J. Shealy
  • Method of reducing the immunogenicity of compounds
    Patent number: 6652863
    Abstract: Reduced-immunogenic fusion compounds are disclosed. The fusion compounds of the invention comprise immunogenic compounds linked to auto-antigenic sequences which render the compound less immunogenic. In addition, a method of reducing the immunogenicity of an immunogenic compound is disclosed. The method comprises linking an auto-antigenic sequence to an otherwise immunogenic compound. Recombinant nucleotide sequences encoding auto-antigenic sequences are also disclosed.
    Type: Grant
    Filed: July 6, 1995
    Date of Patent: November 25, 2003
    Assignee: Centocor, Inc.
    Inventors: Robert E. Jordan, Carrie Lynne Wagner, David M. Knight
  • Methods for sustained drug delivery and compositions useful therefor
    Publication number: 20030198633
    Abstract: Methods for sustained delivery of a therapeutic agent to the circulation of a patient are disclosed. Also disclosed are methods of preparing bioconjugates for sustained delivery of a therapeutic agent to the circulation of a patient.
    Type: Application
    Filed: April 2, 2003
    Publication date: October 23, 2003
    Applicant: Centocor, Inc.
    Inventors: Robert E. Jordan, David M. Knight
  • Anti-IL-12 antibodies, compositions, methods and uses
    Publication number: 20030124123
    Abstract: The present invention relates to at least one novel anti-IL-12 antibodies, including isolated nucleic acids that encode at least one anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Application
    Filed: August 1, 2001
    Publication date: July 3, 2003
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Anti-TNF antibodies, compositions, methods and uses
    Publication number: 20030049725
    Abstract: The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Application
    Filed: August 1, 2001
    Publication date: March 13, 2003
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Chimeric immunoglobulin for CD4 receptors
    Publication number: 20010051709
    Abstract: Chimeric antibodies for CD4 receptor comprising a variable or antigen binding region of a non-human origin specific for CD4 receptor and a constant region of human origin are disclosed. These antibodies are useful as therapeutic agents for autoimmune disorders.
    Type: Application
    Filed: June 29, 2001
    Publication date: December 13, 2001
    Applicant: Centocor, Inc.
    Inventors: John Ghrayeb, David M. Knight, James E. Looney
  • Method of antithrombotic therapy using anti-GPIIb/IIIa antibodies or fragments thereof, including c7E3
    Patent number: 5976532
    Abstract: Platelet-specific, chimeric immunoglobulin and immunoglobulin fragments are described. The chimeric molecules are made up of a nonhuman antigen binding region and a human constant region. Preferred immunoglobulins are specific for glycoprotein IIb/IIIa receptor in its complexed form; they block ligand binding to the receptor and prevent platelet aggregation. The immunoglobulins are useful in anti-thrombotic therapy when administered alone or in conjunction with thrombolytic agents, as well as in thrombus imaging.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: November 2, 1999
    Assignee: Centocor, Inc.
    Inventors: Barry S. Coller, David M. Knight